Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Amy T. Heath"'
Autor:
Amy T. Heath, Stephen R. Marder, John W. Newcomer, John G. Csernansky, James A. Graham, Robert A. Leadbetter, Anne Andorn, Anne Le Moigne, David P. Walling
Publikováno v:
The Journal of clinical psychiatry, vol 82, iss 5
Background: Positive and Negative Syndrome Scale (PANSS) data from a pivotal phase 3 study in participants with schizophrenia of RBP-7000, a recently marketed long-acting subcutaneous injectable risperidone formulation, were examined to determine if
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::028da48f85550c489ff5bdc51b2585b9
https://escholarship.org/uc/item/25s978bk
https://escholarship.org/uc/item/25s978bk
Autor:
Northcutt Allison Ruth, Vanessa Z Ameen, Amy T Heath, William Y. Chey, George E. Dukes, William D. Chey, Eric G. Carter
Publikováno v:
The American Journal of Gastroenterology. 99:2195-2203
To assess long-term safety and efficacy of alosetron in women with severe, chronic diarrhea-predominant IBS and in a subset having more frequent urgency (i.e., bowel urgency at least 10 of 14 days during screening).Randomized patients received either
Autor:
George E. Dukes, David J. McSorley, Jacqueline Harding, William Y. Chey, Amy T Heath, Steven G Wolfe, Mary Kay Washington, Christine M. Hunt
Publikováno v:
The American Journal of Gastroenterology. 96:803-811
Alosetron (Lotronex) is a new therapeutic agent for irritable bowel syndrome (IBS) in women with diarrhea-predominant IBS. This multicenter randomized, double-blind, placebo-controlled study assessed the safety and tolerability of alosetron during lo
Autor:
Christine M. Hunt, Amy T Heath, Gordon F. Kapke, Lynne Hamm, Susan C. Sorrells, Allen W. Mangel, Jacqueline Harding, Northcutt Allison Ruth
Publikováno v:
American Journal of Gastroenterology. 94:1279-1282
OBJECTIVE: Irritable bowel syndrome (IBS) is diagnosed by the presence of a constellation of symptoms fulfilling the Manning or Rome Criteria, after exclusion of organic disease. To exclude other diagnoses that might contribute to the abdominal pain
Autor:
Deborah L. Sykes, Frank L. Lanza, David J. McSorley, Arthur A. Ciociola, Stephen J. Sontag, Amy T Heath
Publikováno v:
Helicobacter. 3:212-221
Background. The combination of ranitidine bismuth citrate (RBC) and clarithromycin (CLR) was compared with each treatment alone for the eradication of H. pylori and healing of duodenal ulcers in patients infected with H. pylori. Methods. This two-pha
Autor:
Sandeep K. Gupta, Deborah A. Smith, Amal Assa'ad, Seema S. Aceves, T. Perschy, Jurgensen Cynthia Holder, Mike Thomson, Amy T Heath, Hector Ortega, Margaret H. Collins
Publikováno v:
Gastroenterology. 141(5)
The role of interleukin (IL)-5 in the pathogenesis of eosinophilic esophagitis (EoE) has been established in animal models; anti-IL-5 therapy has been reported to be effective in adults. We investigated whether IL-5 has a role in accumulation of esop
Autor:
Marquita A. West, Amy T Heath, Vanessa Z. Ameen, Richard Krause, Susan H. Gordon, Eric G. Carter, T. Perschy
Publikováno v:
The American journal of gastroenterology. 102(8)
Alosetron is indicated for women with chronic, severe diarrhea-predominant IBS (d-IBS) who have not responded adequately to conventional therapy. Constipation is the most common adverse event with alosetron treatment. Multiple dosing regimens were as
Autor:
Eric G. Carter, Anthony Lembo, Susan L. Gordon, Kevin W. Olden, Vanessa Z. Ameen, Amy T Heath
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2(8)
The aim of this study was to assess the effect of alosetron on bowel urgency and irritable bowel syndrome (IBS) global improvement in diarrhea-predominant IBS (D-IBS).Women with a lack of satisfactory bowel urgency control at least 50% of the time du
Autor:
Allen W. Mangel, Hahn Ba, George E. Dukes, Northcutt Allison Ruth, S Kong, David J. McSorley, Amy T Heath
Publikováno v:
The Journal of international medical research. 26(2)
Irritable bowel syndrome is characterized by recurrent abdominal pain and altered bowel function. In designing studies to evaluate new treatments for this disease, however, it is difficult to select appropriate endpoints to reflect improvement in the
Publikováno v:
American Journal of Gastroenterology. 101:S411-S412